Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Fennec Pharmaceuticals ( (TSE:FRX) ).
On June 3, 2025, Fennec Pharmaceuticals Inc. held its annual shareholder meeting where all proposals were approved, including the election of six directors and the appointment of Haskell & White LLP as the independent public accounting firm. Additionally, resolutions on executive compensation and amendments to the 2020 Equity Incentive Plan were also passed, reflecting shareholder support for the company’s strategic direction and governance.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$22.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for cancer patients. The company’s primary product is PEDMARK™, a treatment designed to prevent chemotherapy-induced hearing loss in children.
Average Trading Volume: 839
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$310.7M
Find detailed analytics on FRX stock on TipRanks’ Stock Analysis page.